In the study, we have used the Wilms’ tumor gene (WT1) as a biomarker to evaluate its expression in local adult patients with newly diagnosed acute leukemia, including both acute myeloid and lymphoid leukemias (AML and ALL). This evidence concerns the gene WT1 and acute myeloid leukemia.